

# Development of novel reversed-phase packing material for improved separation of protein biopharmaceuticals including intact antibodies

Jeffrey A. Kakaley<sup>1</sup>, Ken Tsutsui<sup>2</sup>, Chiaki Matsumura<sup>2</sup>, Noriko Shoji<sup>2</sup>, Hiroki Kanezaki<sup>2</sup>, and Naohiro Kuriyama<sup>2</sup> <sup>1</sup>YMC America, Inc., <sup>2</sup>YMC Co., Ltd., Japan,

(3.5 µm, 450 Å)

Core-shell type C4 (3.6 µm, 200 Å)

min) 90%B (30-40 min)

1. 5. 6: no elution

### Introduction

On the development and quality control of biopharmaceuticals (proteins, monoclonal antibodies, antibody drug conjugate, etc.), high-performance liquid chromatography (HPLC) is an important tool for analysis and characterization of their structural heterogeneity. We have developed a novel C4 bonded reversed-phase (U)HPLC column named YMC-Triart Bio C4, which is based on organic/inorganic hybrid silica particles with pore diameter of 300 Å, designed for biopharmaceuticals separation. Optimized pore size with narrow pore distribution and advanced surface modification that suppresses interaction between an analyte and residual silanol group improve resolution, peak shape, sensitivity and reproducibility on analyses of biomolecules such as intact and subunits of monoclonal antibodies. In this poster, we will show some examples of effective method development for biopharmaceuticals such as intact monoclonal antibodies and their fragments with this new hybrid C4 column.



LISP class

Base material

Particle size (µm)

Pore size (Å)

Bonding


End-capping

Usable pH range


Temperature limit

(Recommendation

#### **Designed for separation of large proteins**




#### Effect of surface modification on peak shape of proteins and peptides



## High chemical durability Acidic condition (containing 0.1% TFA at 70°C)

Blue : After 125 hr (3,000 column volumes, 150 injections



The chromatograms of protein analysis are compared between Triart Bio C4 column and its prototype which is different in end-capping process. Although the results obtained with 0.1% TFA (upper figures) are comparable the results obtained with 0.1% formic acid (lower figures) are significantly different The optimized end-capping process of Triart Bio C4 suppresses interaction between an analyte and residual silanol group and improves peak shape of proteins with 0.1% formic acid mobile phase 150 X 3.0 mmLD. A) water/TFA or formic acid (100/0.1) B) acetonitrile/TFA or 10-95%B (0-15 min) 0.4 mL/min : 40°C : UV at 220 nm : 4 μL (0.1~ 0.5 mg/ml

is observed on Triart Bio C4 under chemically

harsh condition such as the strongly acidic

: YMC-TriartBio C4 (5 µm, 300 Å) 150 X 3.0 mmI.D. A) water/TFA (100/0.1)


70°C

: 10 µL (0.25 ~ 0.50 mg/mL

20-60%B (0-27 min), 90%B (27-35 min), 20%B (35-50 min 0.4 mL/min

and high temperature.

Fluent



Comparison of protein separation with 0.1% formic acid mobile phase

Method development of simultaneous analysis of Amyloid  $\beta$  (A $\beta$ ) proteins

/brid-based type (3.5 μm, 300 Å)

analysis


(MC-Triart Bio C4 (3 µm, 300 Å)

6 o-Chv

A) water/formic acid (100/0.1)

0.1%TFA. 25°C

: UV at 220 nm



- The combination of newly developed hybrid particles with uniform 300 Å pore diameter and advanced surface modification of YMC-Triart Bio C4 column provide excellent peak shape for a variety of proteins and sufficient chemical durability in wide pH and temperature range. This advantage enables a rapid and efficient method optimization of a complex mixture of peptides and proteins.
- The superior peak shape and intensity even for larger biopharmaceutical proteins such as intact mAbs, mAb fragments and ADCs, are obtained on YMC-Triart Bio C4 with LC/MS compatible mobile phase containing 0.1% formic acid.

www.ymc.co.jp

The difference in retention and peak profiles are

Bio C4 is suitable for mAb characterization.

observed among these mAbs and it shows Triart